Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

REPLBearishLegalnews

Medium materiality6/10

Replimune Faces Securities Class Action After FDA BLA Rejection

Aug 13, 2026, 8:10 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Legal actions against micro-cap biotechs often lead to heightened volatility and further downside risk absent clear settlement or regulatory clarity; historical biotech litigations can erode investor confidence and increase capital costs.

AI summary

What happened, with direct paths to the underlying reporting

Replimune faces a securities class action alleging misstatements around RP1 and the FDA BLA process, timed with the FDA’s April 2026 rejection. The Oct 5, 2026 lead-plaintiff deadline signals a defined litigation window and potential costs, creating downside risk for REPL until the dispute resolves.

Securities class action against REPL filed. Lead plaintiff deadline Oct 5, 2026.
FDA rejection cited RP1 BLA issues. Stock dropped after the news.
Class period: Oct 20, 2025–Apr 10, 2026.
RP1-104 data: 40 patients in early unplanned analysis.
Stock: closed at $4.76 on Apr 10, 2026, and $1.70 on Apr 13.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Replimune Faces Securities Class Action After FDA BLA Rejection

FDA approval of Replimune drug marks first marketed product after setbacks

FDA panel reviews RP1 BLA; August 2026 action date could unlock approval

REPL Faces Securities Probe Following FDA RP1 Concerns, Shares Slump

FDA Efficacy Concerns for Replimune Skin Cancer Drug Ahead of July 30 Meeting